Sep. 25 at 11:10 AM
Leerink🏁
$CTNM Outperform/
$20: Idiopathic pulmonary fibrosis (IPF) might no longer be a drug development graveyard.
There have been two Ph 3 successes in the past year, and
$BMY (OP, Risinger) is advancing an LPA1R antagonist in a large Ph 3 program with data expected
2H26. We like CTNM for their fast-follower approach to LPA1R, with the thesis that BMY's admilparant will be first-in-class while CTNM's PIPE-791 will emerge as the best-in-class program with improved pharmacology. Initiate Outperform, PT
$20.
